This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Zenith Epigenetics Corp.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Eric Campeau: Innovator in Cancer Treatment
Introduction
Eric Campeau is a notable inventor based in Calgary, Canada. He has made significant contributions to the field of cancer treatment, particularly in addressing the challenges posed by triple-negative breast cancer (TNBC). His innovative approach combines various therapeutic agents to enhance treatment efficacy.
Latest Patents
Eric Campeau holds a patent for a groundbreaking invention titled "Combination therapy for the treatment of triple-negative breast cancer." This patent outlines methods for treating TNBC through the co-administration of a BET bromodomain inhibitor and a second therapeutic agent, such as a PARP inhibitor. The specific compounds mentioned include 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine and its derivatives.
Career Highlights
Eric is currently associated with Zenith Epigenetics Corp., where he continues to advance research in cancer therapies. His work is pivotal in developing innovative treatment options for patients suffering from aggressive forms of breast cancer.
Collaborations
Eric collaborates with esteemed colleagues, including Laura M. Tsujikawa and Sanjay Lakhotia. Their combined expertise contributes to the ongoing research and development of effective cancer treatments.
Conclusion
Eric Campeau's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work in combination therapies represents a significant advancement in the fight against triple-negative breast cancer.